Prescient Therapeutics Limited logo

Prescient Therapeutics Limited

ASX:PTX.AX

Overview | Financials
Company Name Prescient Therapeutics Limited
Symbol PTX.AX
Currency AUD
Price 0.041
Market Cap 33,018,120
Dividend Yield 0%
52-week-range 0.037 - 0.105
Industry Biotechnology
Sector Healthcare
CEO Mr. Steven Lee Yatomi-Clarke
Website https://ptxtherapeutics.com

An error occurred while fetching data.

About Prescient Therapeutics Limited

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent

Related Stocks

Kazia Therapeutics Limited logo

Kazia Therapeutics Limited

KZA.AX

0.08 AUD

Cann Group Limited logo

Cann Group Limited

CAN.AX

0.043 AUD

Proteomics International Laboratories Limited logo

Proteomics International Laboratories Limited

PIQ.AX

0.725 AUD

Vita Life Sciences Limited logo

Vita Life Sciences Limited

VLS.AX

2.1 AUD

SomnoMed Limited logo

SomnoMed Limited

SOM.AX

0.31 AUD

SDI Limited logo

SDI Limited

SDI.AX

1.02 AUD

Financials

Numbers are in millions USD

Numbers are in millions USD